Thus with WT mice treated with SPR4-peptide (binds to and inactivates ASARM-motif and peptide), the dramatic increase in 1.25(OH)2D3, hypercalcemia and reduced sclerostin may have helped to counteract the reduced osteocalcin resulting in normal glucose and insulin levels. Here, BGLAP is linked to hypercalcemia disease.